This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bonnema, S. J. Articles by Hegedüs, L. Search for Related Content PubMed PubMed Citation Articles by Bonnema, S. J. Articles by Hegedüs, L.

The Feasibility of High Dose Iodine 131 Treatment as an Alternative to Surgery in Patients with a Very Large Goiter: Effect on Thyroid Function and Size and Pulmonary Function¹

Departments of Endocrinology (S.J.B., L.H.), Nuclear Medicine (H.B., J.M.), Radiology (P.B.A., D.U.K.), and Oncology (L.B.), Odense University Hospital, DK-5000 Odense, Denmark

Address all correspondence and requests for reprints to: Steen Bonnema, M.D., Department of Endocrinology, Odense University Hospital, DK-5000 Odense C, Denmark. E-mail: steen.bonnema{at}dadlnet.dk

Some patients with very large goiters (>150 mL) are not candidates for surgery. We evaluated the feasibility of high dose ¹³¹I in such patients. Twenty-three patients (2 men and 21 women; median age, 67 yr; range, 42–86 yr) with very large goiter (8 toxic) were treated with calculated high dose ¹³¹I [median, 2281 megabecquerels (61.6 mCi); range, 988-4620 megabecquerels (26.7–124.9 mCi)]. During the 12-month observation period, goiter reduction and tracheal anatomy were monitored by magnetic resonance imaging, and the respiratory capacity was monitored by pulmonary function tests.

Five patients (22%) developed hypothyroidism. Thyroid volumes were at baseline, after 1 week, and after 1 yr [mean ± SEM, 311 ± 28, 314 ± 26 (P = NS), and 215 ± 26 (P < 0.01) mL]. The relative changes 1 week after therapy ranged from -14.1% to 15.3%. After 1 yr the mean size was reduced by 33.9% (range, 13.5–61.4%). Only the initial goiter size showed a significant negative correlation to the percent reduction. The smallest cross-sectional area of the trachea decreased 9.2% within 1 week after treatment, but eventually emerged with a 17.9% larger area [mean ± SEM, 84.3 ± 4.8, 75.5 ± 5.1 (P < 0.01), and 98.2 ± 6.0 (P < 0.01) mm²]. The inspiratory parameter, FIF50%, improved after an initial insignificant decline [baseline therapy, after 1 week, after 3 months, and after 1 yr (mean ± SEM), 2.37 ± 0.24, 2.20 ± 0.21 (P = NS), 2.51 ± 0.23 (P = NS), and 2.76 ± 0.25 (P = 0.01) L/s]. FIF50% correlated significantly with the smallest cross-sectional tracheal area (baseline, 1 week, and 1 yr: r = 0.74; P < 0.001, r = 0.63; P < 0.005, and r = 0.46; P < 0.05). Changes in tracheal anatomy did not correlate with changes in either lung dynamics or goiter size. In conclusion, very large goiters can be reduced by a third, on the average, with high dose ¹³¹I therapy without any initial clinically significant tracheal compression. Tracheal cross-sectional area as well as pulmonary inspiratory capacity improve. No serious adverse effects are seen.

This article has been cited by other articles:

				S. J. Bonnema, V. E. Nielsen, H. Boel-Jorgensen, P. Grupe, P. B. Andersen, L. Bastholt, and L. Hegedus Improvement of Goiter Volume Reduction after 0.3 mg Recombinant Human Thyrotropin-Stimulated Radioiodine Therapy in Patients with a Very Large Goiter: A Double-Blinded, Randomized Trial J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3424 - 3428. [Abstract] [Full Text] [PDF]

				V. E. Nielsen, S. J. Bonnema, H. Boel-Jorgensen, P. Grupe, and L. Hegedus Stimulation With 0.3-mg Recombinant Human Thyrotropin Prior to Iodine 131 Therapy to Improve the Size Reduction of Benign Nontoxic Nodular Goiter: A Prospective Randomized Double-blind Trial. Arch Intern Med, July 24, 2006; 166(14): 1476 - 1482. [Abstract] [Full Text] [PDF]

				V. E. Nielsen, S. J. Bonnema, and L. Hegedus Transient Goiter Enlargement after Administration of 0.3 mg of Recombinant Human Thyrotropin in Patients with Benign Nontoxic Nodular Goiter: A Randomized, Double-Blind, Crossover Trial J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1317 - 1322. [Abstract] [Full Text] [PDF]

				O. Cohen, J. Ilany, C. Hoffman, D. Olchovsky, S. Dabhi, A. Karasik, E. Goshen, G. Rotenberg, and S T. Zwas Low-dose recombinant human thyrotropin-aided radioiodine treatment of large, multinodular goiters in elderly patients Eur. J. Endocrinol., February 1, 2006; 154(2): 243 - 252. [Abstract] [Full Text] [PDF]

				C. C. Albino, C. O. Mesa Jr., M. Olandoski, C. E. Ueda, L. C. Woellner, C. A. Goedert, A. M. Souza, and H. Graf Recombinant Human Thyrotropin as Adjuvant in the Treatment of Multinodular Goiters with Radioiodine J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2775 - 2780. [Abstract] [Full Text] [PDF]

				V. E. Nielsen, S. J. Bonnema, and L. Hegedus Effects of 0.9 mg Recombinant Human Thyrotropin on Thyroid Size and Function in Normal Subjects: A Randomized, Double-Blind, Cross-Over Trial J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2242 - 2247. [Abstract] [Full Text] [PDF]

				W.-A. Nieuwlaat, A. R. Hermus, H. A. Ross, W. C. Buijs, M. A. Edelbroek, J. W. Bus, F. H. Corstens, and D. A. Huysmans Dosimetry of Radioiodine Therapy in Patients with Nodular Goiter After Pretreatment with a Single, Low Dose of Recombinant Human Thyroid-Stimulating Hormone J. Nucl. Med., April 1, 2004; 45(4): 626 - 633. [Abstract] [Full Text] [PDF]

				S. J. Bonnema, V. E. Nielsen, and L. Hegedus Pretreatment with a Single, Low Dose of Recombinant Human Thyrotropin Allows Dose Reduction of Radioiodine Therapy in Patients with Nodular Goiter J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 6113 - 6114. [Full Text] [PDF]

				W.-A. Nieuwlaat, D. A. Huysmans, H. C. van den Bosch, C. G. (F. Sweep, H. A. Ross, F. H. Corstens, and A. R. Hermus Pretreatment with a Single, Low Dose of Recombinant Human Thyrotropin Allows Dose Reduction of Radioiodine Therapy in Patients with Nodular Goiter J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3121 - 3129. [Abstract] [Full Text] [PDF]

				L. Hegedus, S. J. Bonnema, and F. N. Bennedbaek Management of Simple Nodular Goiter: Current Status and Future Perspectives Endocr. Rev., February 1, 2003; 24(1): 102 - 132. [Abstract] [Full Text] [PDF]

				S. J. Bonnema, P. B. Andersen, D. U. Knudsen, and L. Hegedus MR Imaging of Large Multinodular Goiters: Observer Agreement on Volume Versus Observer Disagreement on Dimensions of the Involved Trachea Am. J. Roentgenol., July 1, 2002; 179(1): 259 - 266. [Abstract] [Full Text] [PDF]

				W.-A. Nieuwlaat, A. R. Hermus, F. Sivro-Prndelj, F. H. Corstens, and D. A. Huysmans Pretreatment with Recombinant Human TSH Changes the Regional Distribution of Radioiodine on Thyroid Scintigrams of Nodular Goiters J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5330 - 5336. [Abstract] [Full Text] [PDF]